320 related articles for article (PubMed ID: 25524450)
1. Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation.
Bensignor T; Brouquet A; Dariane C; Thirot-Bidault A; Lazure T; Julié C; Nordlinger B; Penna C; Benoist S
Colorectal Dis; 2015 Jun; 17(6):491-8. PubMed ID: 25524450
[TBL] [Abstract][Full Text] [Related]
2. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
5. Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Naiken SP; Toso C; Rubbia-Brandt L; Thomopoulos T; Roth A; Mentha G; Morel P; Gervaz P
BMC Surg; 2014 Jan; 14():4. PubMed ID: 24438090
[TBL] [Abstract][Full Text] [Related]
6. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
7. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
Dellas K; Buller J; Görtz GJ; Richter M; Höhler T; Arnold D; Keck T; Dunst J; Zühlke H
Ann Surg Oncol; 2014 Apr; 21(4):1352-60. PubMed ID: 24306667
[TBL] [Abstract][Full Text] [Related]
8. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.
Marco MR; Zhou L; Patil S; Marcet JE; Varma MG; Oommen S; Cataldo PA; Hunt SR; Kumar A; Herzig DO; Fichera A; Polite BN; Hyman NH; Ternent CA; Stamos MJ; Pigazzi A; Dietz D; Yakunina Y; Pelossof R; Garcia-Aguilar J;
Dis Colon Rectum; 2018 Oct; 61(10):1146-1155. PubMed ID: 30192323
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
10. Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Chitapanarux I; Kamnerdsupaphon P; Lorvidhaya V; Siriwittayakorn P; Tharavichitkul E; Somwangprasert A; Sukthomya V
Gan To Kagaku Ryoho; 2008 Jan; 35(1):77-82. PubMed ID: 18195532
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
12. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy.
Lee SJ; Kang BW; Chae YS; Cho SH; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
Cancer Chemother Pharmacol; 2015 Jul; 76(1):29-34. PubMed ID: 25956708
[TBL] [Abstract][Full Text] [Related]
14. The adequacy of the distal resection margin after preoperative chemoradiotherapy for rectal cancer.
Kim TG; Park W; Choi DH; Kim SH; Kim HC; Lee WY; Park JO; Park YS
Colorectal Dis; 2014 Aug; 16(8):O257-63. PubMed ID: 24422744
[TBL] [Abstract][Full Text] [Related]
15. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
16. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Ishii Y; Hasegawa H; Endo T; Okabayashi K; Ochiai H; Moritani K; Watanabe M; Kitagawa Y
Eur J Surg Oncol; 2010 Nov; 36(11):1061-5. PubMed ID: 20538422
[TBL] [Abstract][Full Text] [Related]
17. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Voogt ELK; Schaap DP; van den Berg K; Nieuwenhuijzen GAP; Bloemen JG; Creemers GJ; Willems J; Cnossen JS; Peulen HMU; Nederend J; van Lijnschoten G; Burger JWA; Rutten HJT
Eur J Surg Oncol; 2021 Sep; 47(9):2429-2435. PubMed ID: 34030921
[TBL] [Abstract][Full Text] [Related]
18. Preoperative Treatment of Locally Advanced Rectal Cancer.
Schrag D; Shi Q; Weiser MR; Gollub MJ; Saltz LB; Musher BL; Goldberg J; Al Baghdadi T; Goodman KA; McWilliams RR; Farma JM; George TJ; Kennecke HF; Shergill A; Montemurro M; Nelson GD; Colgrove B; Gordon V; Venook AP; O'Reilly EM; Meyerhardt JA; Dueck AC; Basch E; Chang GJ; Mamon HJ
N Engl J Med; 2023 Jul; 389(4):322-334. PubMed ID: 37272534
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery.
Kosugi C; Koda K; Tanaka K; Suzuki M; Yamazaki M; Shuto K; Matsuo K; Hirano A; Arimitsu H; Shiragami R; Yasuda H
Hepatogastroenterology; 2015 Jun; 62(140):868-72. PubMed ID: 26902018
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Ihn MH; Kang SB; Kim DW; Oh HK; Lee SY; Hong SM
Dis Colon Rectum; 2014 Aug; 57(8):958-66. PubMed ID: 25003290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
